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Aim: To examine the value of CRUSADE bleeding score in predicting bleeding events in our
local patients with acute coronary syndrome (ACS) in Zagazig University Hospitals.
Methods: Our study included 240 patients with ACS. They underwent history and clinical
examination; 12-lead electrocardiography; echocardiography; troponin I, hematocrit value;
estimated glomerular ﬁltration rate (eGFR); application of CRUSADE score; and follow-up of
the hospital stay and documentations of events. Patients were classiﬁed into two groups:
Group I: patients with major bleeding, and Group II: patients without major bleeding.
Results: Patients with major bleeding were signiﬁcantly older, with more diabetic and hyper-
tensive patients, more prior vascular disease, heart failure, and less patients with unstable
angina, higher heart rate and systolic blood, lower eGFR, and higher CRUSADE risk score.
CRUSADE bleeding score was the strongest predictor of major bleeding. Sensitivity of
CRUSADE score ≥33 in prediction of major bleeding in the whole study group was 80%,
speciﬁcity was 73.4%, positive predictive value was 26.9%, negative predictive value was
96.9%, overall accuracy was 74.1%. Sensitivity of CRUSADE score ≥38.5 in prediction of major
bleeding in the STEMI patients was 70%, speciﬁcity was 84.8%, positive predictive value was
50%, negative predictive value was 92.9%, and overall accuracy was 82.1%.
Conclusion: CRUSADE score is a good predictor for major bleeding in Egyptian patients with
ACS. It is applicable in UA/NSTEMI as well as in STEMI patients and in women as well as in men.
# 2016 Cardiological Society of India. Published by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Coronary artery disease (CAD) is one of the most important
leading causes of death in the whole world.1 Among the* Corresponding author.
E-mail address: m_daydamony@hotmail.com (M.M. Al-Daydamon
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).different clinical presentations of CAD, acute coronary
syndrome (ACS) is the most important and life threatening
condition.2
Different pathogeneses may share in the development of
ACS. However, thrombosis is one of the most important.3y).
B.V. This is an open access article under the CC BY-NC-ND license
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in the management of patients with ACS.4
In spite of their obvious effect, antithrombotic therapies for
ACS signiﬁcantly increase bleeding.5 Hence, it is important to
predict the bleeding risk in ACS patients in order to modify
their treatment aiming to reduce their bleeding events and
improve their outcome.
Various bleeding risk scores were developed and tested.
Among those, CRUSADE (Can Rapid risk stratiﬁcation of
Unstable angina patients Suppress ADverse outcomes with
Early implementation of the ACC/AHA guidelines) is very
signiﬁcant. Bleeding score was found to be the most accurate
in the prediction of major bleeding events.6 However, these
models have not been evaluated for Egyptian situation with
different patients' characteristics and treatment patterns.
The aim of the current study was to examine the value of
CRUSADE bleeding score in predicting the bleeding events in
our local patients with ACS in Zagazig University Hospitals.
2. Methods
Our study took place in Zagazig University Hospitals during the
period from September 2014 to October 2015. Our study
included 240 patients with ACS (145 males and 95 females).
Their age ranged from 41 to 77 years with mean age of
58.1  10.48 years. Patients were included in our study if they
fulﬁlled at least two of the following criteria:
- Presence of typical, chest pain, which is deﬁned as retro-
sternal oppressive or compressive, which occurs at rest or
with minimal exertion lasting for at least 10 min.7
- Electrocardiographic changes in the form of ST-depression,
ST-elevation, or new T-wave inversion.
- Positive cardiac enzymes according to the third universal
deﬁnition of myocardial infarction.8
If there were persistent ST-segment elevation ≥1 mm in at
least two contiguous leads, reciprocal ST-segment depression
≥1 mm in V1 or V2, or presumed new left bundle branch block;Table 1 – Application of CRUSADE bleeding score.
Peridictor Range Score 
Baseline hematocrit <31 9 
31–33.9 7 
34–36.9 3 
37–39.9 2 
Creatinine clearance >15–30 35 
>30–60 28 
>60–90 17 
>90–120 7 
>120 0 
Diabetes mellitus No 0 
Yes 6 
Signs of heart failure No 0 
Yes 7 then patients were considered as having ST-segment Eleva-
tion Myocardial Infarction (STEMI).8 If cardiac biomarkers were
elevated without any of the previous ECG changes; then
patients were considered as having Non-ST-segment Eleva-
tion Myocardial Infarction (NSTEMI).9 Otherwise, patients
were considered as having Unstable Angina (UA).
Patient on oral anticoagulation and patient, who died or
discharged within 48 h of admission were excluded from our
study.
After giving an informed written consent, all patients were
subjected to the following:
1) Full history taking and thorough clinical examination
2) Complete 12-leads electrocardiography
3) Echocardiography: Echocardiographic studies were per-
formed for all patients using Philips IE33 and GE VIVID E9
machines with 2.5 MHz transducers. The left ventricular
ejection fraction (LVEF) was measured using the modiﬁed
Simpson's method from the 2-dimensional apical 4-chamber
view.10
4) Laboratory testing
The following laboratory tests were conducted on all
patients:
- Cardiac troponin I level: at presentation and 6 h after
symptoms onset.4
- Hematocrit level: at admission, at discharge, and when
there is any sign of bleeding.
- Estimated glomerular ﬁltration rate (eGFR) calculation:
eGFR was calculated according to the Cockcroft–Gault
formula.11
5) Application of CRUSADE bleeding risk score according to the
data seen in Table 1.12
6) Treatment of patients
All NSTEMI and UA angina patients were treated
according to the ischemia-guided strategy.4 All patients
received double antiplatelet therapy (aspirin and clopido-
grel) and enoxaparin according to the 2014 guidelines of
AHA/ACC for the management of UA/NSTEMI.
All STEMI patients received thrombolytic therapy with
streptokinase in addition to double antiplatelet (aspirin andPredictor Range Score
Systolic blood pressure 91–100 8
101–120 5
121–180 1
181–200 3
≥201 5
Heart rate 71–80 1
81–90 3
91–100 6
101–110 8
111–120 10
≥121 11
Prior vascular disease No 0
Yes 6
Female sex No 0
Yes 8
Table 2 – Population characteristics and clinical data.
Major bleeding
(n = 26)
No major bleeding
(n = 214)
p
Age (years) 65.1  5.51 57.3  10.64 <0.00001
Sex
Male 14 (53.8%) 131 (61.2%) 0.468
Female 12 (42.2%) 83 (38.8%)
Weight (kg) 78.7  10.94 82.3  14.36 0.128
Diabetes 23 (88.5%) 60 (28%) <0.00001
Hypertension 18 (69.2%) 57 (26.4%) <0.00001
Smoking 3 (11.5%) 44 (20.6%) 0.274
Dyslipidemia 7 (26.9%) 33 (15.4%) 0.137
Prior vascular disease 19 (73.1%) 44 (20.6%) <0.00001
Prior myocardial infarction 6 (23.1%) 41 (19.2%) 0.635
Prior coronary revascularization 3 (11.5%) 53 (24.8%) 0.132
Heart failure on admission 12 (46.2%) 45 (21%) 0.004
ACS type
-UA 4 (15.4%) 88 (41.1%) 0.011
-NSTEMI 12 (46.2%) 80 (37.4%) 0.366
-STEMI 10 (38.4%) 46 (21.5%) 0.055
Heart rate (beat/min) 100.1  22.55 88  15.8 0.0084
Systolic blood pressure (mmHg) 150.8  21.52 127.1  25.78 <0.00001
Baseline hematocrit (%) 3.9  6.12 40.3  4.35 0.259
eGFR (ml/min) 66.5  30.02 96.7  32.37 <0.00001
CRUSADE score 44.7  11.67 28.3  11.93 <0.00001
CRUSADE score ≥33 18 (69.2%) 61 (28.5%) <0.00001
Ejection fraction (%) 57.2  8.61 62.1  9.31 0.0071
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 6 3 2 – 6 3 8634clopidogrel) and enoxaparin according to the 2013 guide-
lines of ACCF/AHA for the management of STEMI.13
7) Follow-up and documentations of in-hospital events
The patients were followed up during their hospital stay,
and the following in-hospital events were documented:
- Mortality.
- In-hospital heart failure.
- Cardiogenic shock.
- Coronary revascularization; with either percutaneous
coronary intervention (PCI) or coronary artery bypass
grafting (CABG).
- Major bleeding: the following bleeding events were
considered as major bleeding: intracranial bleeding,
documented retroperitoneal bleeding, a fall in hematocrit
of 12% from baseline, or any red blood cell transfusion in
which baseline hematocrit was ≥28% or <28% with
clinically documented bleeding. In patients, who under-
went surgical revascularization, only major bleeding
events that occurred before the intervention were taken
into account.12
According to the presence or the absence of major bleeding,
patients were classiﬁed into two groups:
Group I: Patients with major bleeding (26 patients, 14 males
and 12 females, their mean age was 65.1  5.51 years).
Group II: Patients without major bleeding (214 patients, 131
males and 83 females, their mean age was 57.3  10.64 years).
All data were analyzed using the SPSS 19 package program
(SPSS, Chicago, IL, USA). Differences among the study groups
were analyzed by Student's t-test and x2-test. The correlations
among different variables were investigated by Pearson
correlation analysis areas under the ROC curve for clinical
event models were compared using MedCalc version 11.6.1(MedCalc Software, Mariakerke, Belgium). A p value <0.05 was
regarded as being statistically signiﬁcant.
The study protocol had been approved by the Institutional
Review Board of the Faculty of Medicine, Zagazig University.
3. Results
As shown in Table 2, there was no signiﬁcant difference
between the study groups concerning sex, weight, smoking,
dyslipidemia, prior myocardial infarction, prior coronary
revascularization, or baseline hematocrit value.
Patients with major bleeding were signiﬁcantly older than
patients without major bleeding (p < 0.00001). There were
signiﬁcantly more diabetic, more hypertensive, and more
patients with prior vascular disease among major bleeding
group (p < 0.00001 for each). Prior vascular disease was deﬁned
according to the CRUSADE registry (prior stroke and/or
peripheral artery disease).12
On hospital admission, there were signiﬁcantly more
patients in heart failure among major bleeding group
(p < 0.00001).
Regarding the type of ACS, there were signiﬁcantly less
patients presented with UA among major bleeding group
(p = 0.011).
At presentation, patients with major bleeding had signiﬁ-
cantly higher heart rate (p = 0.0084) and systolic blood pressure
(p < 0.00001).
The eGFR was signiﬁcantly lower in patients with major
bleeding than (p < 0.00001). Also, LVEF was signiﬁcantly lower
in (p = 0.0071).
The CRUSADE score was signiﬁcantly higher in patients
with major bleeding (p < 0.00001). Also, there were more
Table 3 – In-hospital events and outcome.
Major
bleeding
(n = 26)
No major
bleeding
(n = 214)
p
Death 1 (3.8%) 10 (4.7%) 0.849
In-hospital heart failure 8 (30.8%) 27 (12.6%) 0.013
Cardiogenic shock 2 (7.7%) 10 (4.7%) 0.505
PCI 13 (42.3%) 62 (29%) 0.029
CABG 2 (7.7%) 9 (4.2%) 0.442
Table 4 – Regression analysis.
Variables Score Degree
of freedom
p
CRUSADE score 37.48 1 <0.00001
Diabetes mellitus 37.415 1 <0.00001
Prior vascular disease 33.027 1 <0.00001
Basal hematocrit 20.078 1 <0.00001
Hypertension 19.578 1 <0.00001
eGFR 18.977 1 <0.00001
Systolic blood pressure 18.733 1 0.00034
Age 12.934 1 0.00052
Heart rate 11.71 1 0.0015
Heart failure during hospital 6.133 1 0.013
Heart failure at admission 0.162 1 0.687
Fig. 1 – ROC curve for CRUSADE score with major bleeding
events in total population.
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bleeding (p < 0.00001).
Regarding in-hospital outcome, as shown in Table 3, there
was no signiﬁcant difference between the two groups
regarding death, developing cardiogenic shock, or doing CABG.
In patients with major bleeding, more patients developed
heart failure during hospital stay (p = 0.013). Also, more
patients had undergone PCI during hospital stay (p = 0.029).
Regression analysis of the relation of different parameters
to the development of major bleeding is shown in Table 4.
CRUSADE bleeding score was the strongest independent
predictor of major bleeding (p < 0.00001). Other signiﬁcant
independent predictors were in order of signiﬁcance: diabetes
mellitus, prior vascular disease, basal hematocrit, hyperten-
sion, eGFR (p < 0.00001 for each), systolic blood pressure
(p = 0.00034), age ( p = 0.00052), heart rate (p = 0.0015), and
heart failure during hospital stay (p = 00.013).
The validity of CRUSADE score ≥33 in prediction of major
bleeding in the whole study group is shown in Table 5.
Sensitivity of was 80%, speciﬁcity was 73.4%, positive predic-
tive value was 26.9%, negative predictive value was 96.9%, and
overall accuracy was 74.1%, p = 0.0013. The receiver operatingTable 5 – Validity of CRUSADE score in prediction of major ble
Major bleeding 
CRUSADE < 33 5 
CRUSADE ≥ 33 21 
Total 26 
Sensitivity Speciﬁcity PPP NPV 
80% 73.4% 26.9% 96.9% 
PPV, positive predictive value; NPV, negative predictive value.characteristic (ROC) curve analysis is shown in Fig. 1, and area
under ROC-curve is 0.85.
The validity of CRUSADE score ≥38.5 in prediction of major
bleeding among STEMI patients is shown in Table 6. Sensitivity
of was 70%, speciﬁcity was 84.8%, positive predictive value was
50%, negative predictive value was 92.9%, and overall accuracy
was 82.1%, p = 0.00021. The ROC curve analysis is shown in
Fig. 2, and area under ROC-curve was 0.79.
The validity of CRUSADE score ≥36 in prediction of major
bleeding among women is shown in Table 7. Sensitivity of was
66.7%, speciﬁcity was 89.2%, positive predictive value was
47.1%, negative predictive value was 94.9%, and overall
accuracy was 86.3%, p = 0.00008. The ROC curve analysis is
shown in Fig. 3, area under ROC-curve was 0.89.
The rates of major bleeding in different CRUSADE score
groups are shown in Table 8. The rate of bleeding was 3.4% in
patients with very low risk (score ≤20), 5.6% in patients with
low risk (score 21–30), 12.1% in patients with moderate risk
(score 31–40), 25.8% in patients with high risk (score 41–50), and
was 35.3% in patients with very high risk (score >50).
4. Discussion
Hemorrhagic complications are the most common non-
ischemic complications encountered in patients with ACS.
The frequency of major hemorrhaging oscillates between 2%eding in all patients.
No major bleeding Total
157 162
57 78
214 240
Overall accuracy Kappa p
74.1% 0.28 0.0013
Table 6 – Validity of CRUSADE score in prediction of major bleeding in STEMI patients.
Major bleeding No major bleeding Total
CRUSADE < 38.5 3 39 42
CRUSADE ≥ 38.5 7 7 14
Total 10 46 56
Sensitivity Speciﬁcity PPP NPV Overall accuracy Kappa p
70% 84.8% 50% 92.9% 82.1% 0.47 0.00021
PPV, positive predictive value; NPV, negative predictive value.
Table 7 – Validity of CRUSADE score in prediction of major bleeding in women.
Major bleeding No major bleeding Total
CRUSADE < 36 4 74 78
CRUSADE ≥ 36 8 9 17
Total 12 83 95
Sensitivity Speciﬁcity PPP NPV Overall accuracy Kappa p
66.7% 89.2% 47.1% 94.9% 86.3% 0.53 0.00008
PPV, positive predictive value; NPV, negative predictive value.
Fig. 2 – ROC curve for CRUSADE score with major bleeding
events in STEMI population.
Fig. 3 – ROC curve for CRUSADE score with major bleeding
events in women.
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 6 3 2 – 6 3 8636and 9% across the spectrum of ACS without ST-segment
elevation, largely depending on the deﬁnition and the type of
treatment used, particularly the dose of antithrombotic agents
prescribed and the invasive procedures undertaken.14
The present study was done to test the validity of the
CRUSADE bleeding risk model in the prediction of major
bleeding in Egyptian patients with ACS, either UA/NSTEMI or
STEMI.
Although the CRUSADE score was developed by using the
database of patients with high-risk non-ST-elevation ACSs
admitted in American hospitals, of whom only less than 1%
were of Middle Eastern origins,15 our results showed that the
validity of the CRUSADE bleeding risk model in Egyptian
patients with ACS was more or less satisfactory, either in
patients with UA/NSTEMI or STEMI.
Several published studies demonstrated successful use of
CRUSADE score in the prediction of major bleeding in different
populations with ACS from various Western countries. Abu-
Assi et al. evaluated the validity of the CRUSADE bleeding risk
score in a cohort of 782 hospitalized patients with UA/NSEMI in
a Spanish population. They have found that The CRUSADE risk
score was generally validated and found to be useful in the
Spanish cohort of patients treated with or without multiple
antithrombotic therapy either they underwent cardiac cathe-
terization or not.16
Also, Kharchenko and his colleagues had studied the
prognostic value of CRUSADE bleeding risk score in 602 patientsTable 8 – CRUSADE score groups and major bleeding.
CRUSADE risk Total number Major bleeding
Very low (≤20) 56 2 (3.4%)
Low (21–30) 85 5 (5.6%)
Moderate (31–40) 39 5 (12.1%)
High (41–50) 23 8 (25.8%)
Very high (>50) 11 6 (35.3%)
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 6 3 2 – 6 3 8 637with UA/NSTEMI, who were admitted to a Moscow community
noninvasive hospital. They found sensitivity and speciﬁcity of
the CRUSADE score for major and moderate bleedings during
hospitalization were 77% and 52%, respectively; with area under
ROC-curve was 0.68.17
Boden et al. had studied the risk of in-hospital major
CRUSADE bleeding and 1-year mortality after primary PCI for
965 Dutch STEMI patients, who received abciximab, peripro-
cedural heparin and loading doses of aspirin and clopidogrel.
They had found that major bleeding was common after
primary PCI for STEMI and associated with increased mortality
during 1-year follow-up. However, they found that the
CRUSADE bleeding risk score had underestimated the risk of
major bleeding, and they concluded that the use of this score
might be limited in STEMI patients.18
The CRUSADE bleeding risk score has been evaluated not
only in North America and Western Europe, but also in the Far
East. Jinatongthai et al. had studied the validity of CRUSADE
score in predicting major bleeding in Thai patients with ACS
receiving enoxaparin. They had found that the CRUSADE
model demonstrated a satisfactory discriminatory capacity for
the entire study population (C = 0.688), UA (C = 0.591), NSTEMI
(C = 0.693), and STEMI groups (C = 0.736). They concluded that
CRUSADE risk score was able to estimate in-hospital major
bleeding of Thai patients with ACS, who received treatment
with enoxaparin.19
The wide applicability of CRUSADE risk score in an
extensive range of population may be explained by many
reasons. The score was developed from a very large patient
registry from a real-life practice, so its variables were widely
applicable in many different situations. Many variables in
CRUSADE, such as female gender, low baseline hematocrit,
and presence of organ failure such as heart or kidney failure
were commonly identiﬁed and used by other bleeding risk
models.20,21
Although we have found that CRUSADE risk score was a
good predictor of major bleeding in the whole group and in
STEMI subgroup, however, we did not ﬁnd signiﬁcant differ-
ence between patients with and without major bleeding
regarding hospital mortality. This result was discordant to the
results found by Amador et al., as they found a strong relation
between major bleeding and hospital mortality. They also
found that CRUSADE bleeding risk score was as valid as
ischemia risk score like TIMI and GRACE risk scores in
predicting mortality.22
The rates of bleeding in our study were higher than those
found by the original CRUSADE investigators.12 These
differences were much obvious among patients with high
risk (25.8% in our results versus 11.9% in CRUSADE), and
among patients with very high risk (35.3% % in our results
versus 19.5% in CRUSADE). These differences may be
explained by the center, where the study was done, Zagazig
University Hospital, which is a tertiary hospital to which
patients with more severe diseases and co-morbidities are
referred. Other possible explanation is the endemic diseases
that are more common in Egypt and may affect the
coagulation proﬁle like hepatitis C virus (HCV), as the highest
prevalence of HCV infection around the world was found to be
in Egypt (15–20%), while its global prevalence was found to
be 2.2%.235. Conclusion
- CRUSADE bleeding risk score is a good predictor for major
bleeding among Egyptian patients with ACS.
- Application of CRUSADE bleeding risk score may be helpful
in Egypt.
- The risk was found to be applicable in UA/NSTEMI as well as
in STEMI patients, and in women as well as in men.
Study limitations
 Relatively small number of patients.
 The study was done in a single center.
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